Compare Ascendis Pharma A/S (ASND) vs Chevron Corp (CVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Chevron Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Chevron Corp trades at $177.77 (market cap $351.32B). The key difference: Chevron Corp is far larger — about 19.8× Ascendis Pharma A/S's market cap, and Chevron Corp pays a 4.04% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CVX | |
|---|---|---|
Market Cap | $17.74B | $351.32B |
Sector | Health | Energy |
52-Week High | $277.18 | $211.14 |
52-Week Low | $163.32 | $146.72 |
Enterprise Value | $18.11B | $391.42B |
Volume | — | 9,807,834 |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Chevron (CVX) trades at $176.40, up 1.35% today, with a neutral technical signal and strong analyst consensus. Recent earnings beat expectations, though revenue and net income have declined year-over-year. The company maintains solid cash flow from operations and announced a $13.8 billion investment in Argentina. A dividend of $1.78 per share is scheduled for payment on June 10, 2026.
CVX offers value with a consensus price target of $207.56, implying 17.6% upside, supported by high oil prices and strategic expansions. Risks include volatile energy markets, geopolitical tensions affecting supply chains, and declining profit margins. Institutional sentiment remains bullish despite near-term earnings pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
